Publication date: Jan 01, 2025
Richter transformation is still a serious risk in the era of innovative therapies, despite the fact that targeted therapy with Bruton’s tyrosine kinase inhibitor has significantly improved the prognosis for chronic lymphocytic leukemia (CLL). We report a rare case of a 61-year-old male patient’s CLL transforming into a synchronous clonal related plasmablastic lymphoma (PBL) after receiving ibrutinib. During COVID-19, the patient stopped taking ibrutinib, which caused the illness to worsen. Histology revealed that PBL was present in the right supraclavicular mass and that CLL had penetrated the bone marrow. Three cycles of CHP (cyclophosphamide, doxorubicin, and prednisone) were administered together with venetoclax and brentuximab vedotin. After receiving BCMA CAR-T cell treatment, the patient was in complete remission. For PBL transformation, a condition with a worse prognosis and few therapy choices, our results suggest the use of BCMA CAR-T and novel target agents.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | plasmablastic lymphoma |
| disease | MESH | chronic lymphocytic leukemia |
| drug | DRUGBANK | Ibrutinib |
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Cyclophosphamide |
| drug | DRUGBANK | Doxorubicin |
| drug | DRUGBANK | Prednisone |
| drug | DRUGBANK | Venetoclax |
| drug | DRUGBANK | Brentuximab vedotin |
| disease | IDO | cell |
| disease | MESH | in complete remission |
| drug | DRUGBANK | Adenine |
| disease | MESH | Cell Transformation Neoplastic |